{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:19:27Z","timestamp":1793963967813,"version":"4.8.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1053\/j.gastro.2021.11.002","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T20:58:18Z","timestamp":1636405098000},"page":"757-771.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":209,"title":["Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)"],"prefix":"10.1053","volume":"162","author":[{"given":"Grishma","family":"Hirode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah S.J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Van Hees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia M.","family":"Brakenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.11.002_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2021.11.002_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jvh.12997","article-title":"Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up","volume":"26","author":"Campenhout","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2021.11.002_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2021.11.002_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.25937","article-title":"Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy","volume":"57","author":"Lai","year":"2013","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.11.002_bib11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2021.11.002_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12072-016-9738-1","article-title":"HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy","volume":"10","author":"Dusheiko","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2021.11.002_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.11.002_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/gutjnl-2013-306221","article-title":"HBsAg seroclearance with NUCs: rare but important","volume":"63","author":"Cornberg","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2013negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD Guidelines for Treatment of Chronic Hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients \u2013 FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib21","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib22","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0168-8278(20)30755-8","article-title":"Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop-NUC trial","volume":"73","author":"van B\u00f6mmel","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib23","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep4.1247","article-title":"Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis","volume":"2","author":"Ford","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2021.11.002_bib24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","article-title":"Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir","volume":"113","author":"Shin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.11.002_bib25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hep.29821","article-title":"Less can be more: a finite treatment approach for HBeAg-negative chronic hepatitis B","volume":"68","author":"Lampertico","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/apt.13409","article-title":"Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis","volume":"42","author":"Chen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib27","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2021.11.002_bib29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2021.11.002_bib30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib31","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/cells9020493","article-title":"Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B","volume":"9","author":"Papatheodoridi","year":"2020","journal-title":"Cells"},{"key":"10.1053\/j.gastro.2021.11.002_bib34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2021.04.040","article-title":"The times they are a-changing \u2013 a refined proposal for finite HBV nucleos(t)ide analogue therapy","volume":"75","author":"Berg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1053\/j.gastro.2019.10.050","article-title":"Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B","volume":"158","author":"Liem","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.11.002_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jvh.12683","article-title":"Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy","volume":"24","author":"Hung","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2021.11.002_bib37","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.3748\/wjg.v21.i28.8653","article-title":"Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients","volume":"21","author":"Ge","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.11.002_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-02010-w","article-title":"Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg \u2264 200 IU\/mL","volume":"7","author":"Yao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2021.11.002_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.11.002_bib41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"Daring-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib42","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2021.11.002_bib43","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.14560","article-title":"Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes","volume":"47","author":"Van Hees","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib45","first-page":"1","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2021.11.002_bib47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1053\/j.gastro.2021.11.002_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.30474","article-title":"The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.13654","article-title":"Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B","volume":"38","author":"van B\u00f6mmel","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2021.11.002_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2021.11.002_bib51","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/infdis\/jit209","article-title":"Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers","volume":"208","author":"Tseng","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2021.11.002_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v11080687","article-title":"Caucasian ethnicity, but not treatment cessation is associated with hbsag loss following nucleos(T)ide analogue-induced HBeAg seroconversion","volume":"11","author":"Van Hees","year":"2019","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2021.11.002_bib55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","article-title":"Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2021.11.002_bib56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2021.11.002_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0220376","article-title":"Genomic modeling of hepatitis B virus integration frequency in the human genome","volume":"14","author":"Podlaha","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.11.002_bib58","first-page":"1","article-title":"Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2021.11.002_bib59","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib61","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib62","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2021.11.002_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/jiy350","article-title":"Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients","volume":"218","author":"H\u00f6ner Zu Siederdissen","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2021.11.002_bib64","first-page":"S751","article-title":"Earlier and more frequent virological and clinical relapse after cessation of tenofovir disoproxil fumarate versus entecavir therapy: results from a global, multi-ethnic cohort of patients with chronic hepatitis B virus infection (RETRACT-B Study )","volume":"75","author":"Choi","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1 Suppl","key":"10.1053\/j.gastro.2021.11.002_bib65","first-page":"490A","article-title":"Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide (TAF) relative to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients treated for 5 years in 2 ongoing phase 3 studies","volume":"72","author":"Chan","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib66","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1053\/j.gastro.2018.03.066","article-title":"HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients","volume":"154","author":"Liaw","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.11.002_bib67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hep.31525","article-title":"Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat","volume":"73","author":"Liaw","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib68","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/gutjnl-2019-320341","article-title":"Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients","volume":"69","author":"Liaw","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib69","first-page":"S749","article-title":"Hepatic decompensation and hepatocellular carcinoma after stopping nucleos (t)ide analogue therapy: results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"75","author":"Hirode","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib71","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib72","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","article-title":"Long-Term outcomes in hepatitis B: the REVEAL-HBV Study","volume":"11","author":"Chen","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.gastro.2021.11.002_bib73","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","article-title":"Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift","volume":"13","author":"Liaw","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2021.11.002_bib74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.11.002_bib75","first-page":"522A","article-title":"Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy","volume":"72","author":"Zhang","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.11.002_bib76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.51.4.597","article-title":"Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B","volume":"51","author":"Lim","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.11.002_bib77","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra-long-term follow-up of interferon alfa treatment for HBeAg-positive chronic hepatitis B virus infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.11.002_bib78","series-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed","author":"Harrell","year":"2015"}],"updated-by":[{"DOI":"10.1053\/j.gastro.2024.03.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521037239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521037239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:51:07Z","timestamp":1726069867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521037239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0016508521037239"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.11.002","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}